Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR6 | P50406 | 11/20 | 0.62 |
| ▸ | GHSR | Q92847 | 8/20 | 0.41 |
| ▸ | GRM5 | P41594 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6549721 | 1.00 | HTR6 (0.62) | HTR6GHSRGRM5 | |
| SCHEMBL3613058 | 0.84 | GHSR (0.43) | HTR6GHSR | |
| SCHEMBL3613062 | 0.84 | GHSR (0.43) | HTR6GHSR | |
| SCHEMBL6548713 | 0.77 | HTR6 (0.71) | HTR6 | |
| SCHEMBL3323330 | 0.77 | HTR6 (1.00) | HTR6 | |
| SCHEMBL4312655 | 0.76 | GHSR (0.56) | GHSR | |
| SCHEMBL4676469 | 0.74 | HTR6 (0.66) | HTR6GHSR | |
| SCHEMBL6047105 | 0.73 | GHSR (0.64) | GHSR | |
| SCHEMBL1381340 | 0.73 | GHSR (0.49) | HTR6GHSR | |
| SCHEMBL6549576 | 0.73 | HTR6 (0.90) | HTR6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1478361-A2 | ARYLSULFONE DERIVATIVES | PHARMACIA & UPJOHN COMPANY (US) | 2004-11-24 | — | — | EP | claimed |
| US-20030220325-A1 | Such as 1-(4-(phenylsulfonyl)-naphthyl)piperazine; for treating treating diseases related to 5-HT receptor; radiolabelling | PHARMACIA & UPJOHN COMPANY | 2003-11-27 | — | — | US | claimed |
| WO-2003072558-A2 | ARYLSULFONE DERIVATIVES | PHARMACIA & UPJOHN COMPANY (US) | 2003-09-04 | — | — | WO | claimed |
| EP-1478361-A2 | ARYLSULFONE DERIVATIVES | PHARMACIA & UPJOHN COMPANY (US) | 2004-11-24 | — | — | EP | disclosed |
| US-20030220325-A1 | Such as 1-(4-(phenylsulfonyl)-naphthyl)piperazine; for treating treating diseases related to 5-HT receptor; radiolabelling | PHARMACIA & UPJOHN COMPANY | 2003-11-27 | — | — | US | disclosed |
| WO-2003072558-A2 | ARYLSULFONE DERIVATIVES | PHARMACIA & UPJOHN COMPANY (US) | 2003-09-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030220325-A1 | Such as 1-(4-(phenylsulfonyl)-naphthyl)piperazine; for treating treating diseases related to 5-HT receptor; radiolabelling | HTR6, TPH1, HTR5A | HTR6 1/4885GHSR 121/4885GRM5 69/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.